Lupus
TheDaoIndex KDAO2011
3 years 3 months ago
OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis targets (proteinuria < 0.7 mg/mg and pred < 7.5 mg/d) at 1 year @AuriniaPharma #EULAR2022 @rheumnow https://t.co/0GoCgP98F2
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye because they can potentially impact medical practice.
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases, with many theoretically well-founded agents appearing to have failed in clinical trials as a result of inefficacy, problem with trial design and/or safety issues.
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
In a rush for a quick update on selected trial results in #lupus presented at #EULAR2022? Please find my article https://t.co/0XTkPRr6kQ @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
#POS0716 #EULAR2022 Systematic review and meta-analysis of 7 studies (i.e. only 1 x proof of concept RCT) showed high SRI-4 response rate (82%) in #lupus patients treated on IL2. Injection reaction (33%) and Fever (24%). Promising and definitive RCT is needed @RheumNow https://t.co/BBcgt11yNT
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
#POS0713 #EULAR2022 Exploratory analyses from Phase 2 RCT showed numerically more patients treated with BIIB059, a BDCA2 inhibitor achieved a clear (CLASI of 0-1) and almost clear cutaneous #lupus (CLASI 0-3). Looking forward to Phase 3 results in the next few years @RheumNow https://t.co/dDbwYCx7zT
Dr. John Cush RheumNow
3 years 3 months ago
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
#POS0709 #EULAR2022 Pooled analyses of TULIP-1 & -2 RCTs showed sustained & #lupus patients spent longer time in BICLA response vs Placebo up to 52 Wks. BILAG response was sustained in MSK, skin and constitutional domains. Be interesting to see longer follow-up data @RheumNow https://t.co/kNk7WFloLf
Aurelie Najm AurelieRheumo
3 years 3 months ago
B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬
FCGR3A-158V:
*encodes the allotype ⬆️ affinity for IgG1
*is associated w/ clinical and biological responses in RA and SLE.
A new way to stratify pts for anti-CD20 therapy?
@Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71
TheDaoIndex KDAO2011
3 years 3 months ago
“I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow
Janet Pope Janetbirdope
3 years 3 months ago
#SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
#EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC
Poster Hall